PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Miranda D Grounds Selected Research
Necrosis
07/2008
Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle.
10/2006
Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
08/2006
Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice.
11/2004
Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.
04/2004
Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.
Articles by Research Topic
Disease
5
Necrosis
07/2008 - 04/2004
1
Muscular Dystrophies (Muscular Dystrophy)
01/2008
1
Inflammation
06/2005
1
Atrophy
02/2005
Drug/Important Bio-Agent (IBA)
2
TNFR-Fc fusion protein (etanercept)
FDA Link
10/2006 - 06/2005
2
infliximab (Remicade)
FDA Link
06/2005 - 04/2004
2
Insulin-Like Growth Factor I (IGF-1)
IBA
02/2005 - 11/2004
1
Insulin (Novolin)
FDA Link
07/2008
1
Cromolyn Sodium (Cromoglicic Acid)
FDA Link
Generic
08/2006
Therapy/Procedure
1
Autologous Transplantation (Autograft)
01/2008
1
Transplants (Transplant)
06/2005
1
Denervation
02/2005